Literature DB >> 29208302

Efficacy of infliximab biosimilars in patients with Crohn's disease.

Pierre Michetti1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29208302     DOI: 10.1016/S0140-6736(17)32459-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  2 in total

1.  Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease.

Authors:  Viktoria Bergqvist; Mohammad Kadivar; Daniel Molin; Leif Angelison; Per Hammarlund; Marie Olin; Jörgen Torp; Olof Grip; Stefan Nilson; Erik Hertervig; Jan Lillienau; Jan Marsal
Journal:  Therap Adv Gastroenterol       Date:  2018-10-11       Impact factor: 4.409

2.  Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials.

Authors:  Kristin K Jørgensen; Guro L Goll; Joe Sexton; Nils Bolstad; Inge C Olsen; Øivind Asak; Ingrid P Berset; Ingrid M Blomgren; Katrine Dvergsnes; Jon Florholmen; Svein O Frigstad; Magne Henriksen; Jon Hagfors; Gert Huppertz-Hauss; Espen A Haavardsholm; Rolf A Klaasen; Bjørn Moum; Geir Noraberg; Ulf Prestegård; Jan H Rydning; Liv Sagatun; Kathrine A Seeberg; Roald Torp; Cecilia Vold; David J Warren; Carl M Ystrøm; Knut E A Lundin; Tore Kvien; Jørgen Jahnsen
Journal:  BioDrugs       Date:  2020-10       Impact factor: 5.807

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.